Current Report Filing (8-k)
March 10 2023 - 2:44PM
Edgar (US Regulatory)
0001579428false00015794282023-03-102023-03-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): March 10, 2023 |
Axsome Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-37635 |
45-4241907 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
22 Cortlandt Street, 16th Floor |
|
New York, New York |
|
10007 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (212) 332-3241 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Common Stock, Par Value $0.0001 Per Share |
|
AXSM |
|
Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On March 10, 2023, Axsome Therapeutics, Inc. (the “Company”), provided the following update regarding its liquidity position and relationship with Silicon Valley Bank (“SVB”).
The Company has material cash deposits with both SVB and Citibank. Notwithstanding, the Company believes that its current cash held at Citibank, along with the remaining committed capital from its $350 million term loan facility with Hercules Capital, is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan. Additionally, the FDIC has announced that it will pay SVB depositors an advance dividend within the next week; this forecast does not take into account such funds.
The information in this Item 7.01 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
Axsome Therapeutics, Inc. |
|
|
|
|
Date: |
March 10, 2023 |
By: |
/s/ Herriot Tabuteau, M.D. |
|
|
Name: Title: |
Herriot Tabuteau, M.D.
President and Chief Executive Officer
|
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Dec 2023 to Dec 2024
